Lupin, a company in the Pharmaceuticals industry, reported revenue of ₹7,827 crore and net profit of ₹1,155 crore for the September 2026 quarter.
Lupin (NSE: LUPIN) closed at ₹2,014.00 on 20 Nov 2026, down 0.8% over the past year. Its market capitalisation is ₹92,099 crore and it trades at 16.4 times earnings.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.